References
- Robak T, Szmigielska-Kapłon A, Pluta A et al. Novel and emerging drugs for acute myeloid leukemia:pharmacology and therapeutic activity. Curr Med Chem 2011;18:638–666.
- Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:89–99.
- Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance:a major contributor to minimal residual disease. Nat Rev Cancer 2009;9:665–674.
- Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol 2000;228:151–165.
- Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006;107:2223–2233.
- Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649–661.
- Palomero T, Ferrando A. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma 2009;9(Suppl. 3):205–210.
- Milner LA, Kopan R, Martin DI, et al. A human homologue of the Drosophila developmental gene, Notch, is expressed in CD34 + hematopoietic precursors. Blood 1994;83:2057–2062.
- Tohda S, Nara N. Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk Lymphoma 2001;42:467–472.
- Xu X, Zhao Y, Xu M, et al. Activation of Notch signal pathway is associated with a poorer prognosis in acute myeloid leukemia. Med Oncol 2011;28(Suppl 1):483–489.
- Chiaramonte R, Basile A, Tassi E, et al. A wide role for NOTCH1 signaling in acute leukemia. Cancer Lett 2005;219:113–120.
- Tohda S, Murata-Ohsawa M, Sakano S, et al. Notch ligands, Delta-1 and Delta-4 suppress the self-renewal capacity and long-term growth of two myeloblastic leukemia cell lines. Int J Oncol 2003;22:1073–1079.
- Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
- Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075–4083.
- Holowiecki J, Grosicki S, Kyrcz-Krzemien S, et al. Addition of cladribine to the standard daunorubicine–cytarabine (DA 3 + 7) remission induction protocol (DAC) contrary to adjunct of fludarabine (DAF) improves the overall survival in untreated adults with acute myeloid leukemia aged up to 60 Y: a multicenter, randomized, phase III PALG AML 1/2004 DAF/DAC/DA study in 673 patients. Blood 2008;112(Suppl. 1): Abstract 133.
- Del Giudice I, Rossi D, Chiaretti S, et al. NOTCH1 mutations in + 12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of + 12 CLL. Haematologica 2012;97: 437–441.
- Kanamori E, Itoh M, Tojo N, et al. Flow cytometric analysis of Notch1 and Jagged1 expression in normal blood cells and leukemia cells. Exp Ther Med 2012;4:397–400.
- Lobry C, Ntziachristos P, Ndiaye-Lobry D, et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med 2013;210:301–319.
- Kannan S, Sutphin RM, Hall MG, et al. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp Med 2013;210:321–337.
- Ascano JM, Beverly LJ, Capobianco AJ. The C-terminal PDZ-ligand of JAGGED1 is essential for cellular transformation. J Biol Chem 2003;278:8771–8779.